| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.venusremedies.com | |
| Market Cap | 338.05 Cr. | |
| Enterprise Value(EV) | 337.65 Cr. | 2021-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 56.56 | Trailing Twelve Months Ending 2021-12 |
| Price-Earning Ratio (PE) | 4.45 | Trailing Twelve Months Ending 2021-12 |
| Industry PE | 28.96 | Trailing Twelve Months Ending 2021-12 |
| Book Value / Share | 329.86 | Trailing Twelve Months Ending 2021-12 |
| Price to Book Value | 0.76 | Calculated using Price: 251.45 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 1.34 Cr. | 13,366,988 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Venus Remedies incorporated in 1989, is a pharmaceutical manufacturing company. The company provides formulations in area of anti-biotics and oncological therapeutics. Company has two manufacturing facilities located in India and Germany. Company manufactures Oncological and Cefelosporine Injectable products. Its manufacturing facility located in India has received ISO 9001, ISO, 14001 and OHSAS 18001 for quality management. Its Germany facility follows EU-GMP norms. Presently, the company has successfully made its presence in the markets of Philippines, Thailand, Malaysia, Cambodia, Burma, Vietnam, Sri Lanka, Pakistan, Bangladesh, Nepal, Uganda, Kenya, Botswana, Zimbabwe, Sudan, Mauritius, Yemen, Iraq, Russia, Belarus, Ukraine, Costa Rica, Venezuela, Guatemala, Peru, Colombia, Ecuador, Syria, Yeman, Togo, Saudi Arbia and Iraq. Company has entered into strategic alliances with various pharmaceutical companies to launch its R&D based specialty products. It has tie-ups with companies namely IPCA Laboratories, Elder Pharmaceuticals, Shreya Lifesciences, Cadila Healthcare, Glenmark Pharmaceuticals, Marksans Pharma, Indoco Remedies, Karle Health Sciences, Lupin and Jagsonpal Pharmaceuticals. Company also conducts in-house research and development activities that focuses Formulation Development, NDDS (Novel Drug Delivery System), new formulations of off patented chemicals and analytical and chemical research. Products The company is engaged in manufacturing products catering various segments such as Oncology, Cephalosporins, Carbapenems and Other Specialties, Intravenous Products, Vials/Lyophilized Injectables, Pre-Filled Syringes, Hormones, Ampoules and Biological Products. Milestone/ Awards 2009 |
||
Company Profile
Venus Remedies incorporated in 1989, is a pharmaceutical manufacturing company. The company provides formulations in area of anti-biotics and oncological therapeutics.
Company has two manufacturing facilities located in India and Germany. Company manufactures Oncological and Cefelosporine Injectable products.
Its manufacturing facility located in India has received ISO 9001, ISO, 14001 and OHSAS 18001 for quality management. Its Germany facility follows EU-GMP norms.
Presently, the company has successfully made its presence in the markets of Philippines, Thailand, Malaysia, Cambodia, Burma, Vietnam, Sri Lanka, Pakistan, Bangladesh, Nepal, Uganda, Kenya, Botswana, Zimbabwe, Sudan, Mauritius, Yemen, Iraq, Russia, Belarus, Ukraine, Costa Rica, Venezuela, Guatemala, Peru, Colombia, Ecuador, Syria, Yeman, Togo, Saudi Arbia and Iraq.
Company has entered into strategic alliances with various pharmaceutical companies to launch its R&D based specialty products. It has tie-ups with companies namely IPCA Laboratories, Elder Pharmaceuticals, Shreya Lifesciences, Cadila Healthcare, Glenmark Pharmaceuticals, Marksans Pharma, Indoco Remedies, Karle Health Sciences, Lupin and Jagsonpal Pharmaceuticals.
Company also conducts in-house research and development activities that focuses Formulation Development, NDDS (Novel Drug Delivery System), new formulations of off patented chemicals and analytical and chemical research.
Products
The company is engaged in manufacturing products catering various segments such as Oncology, Cephalosporins, Carbapenems and Other Specialties, Intravenous Products, Vials/Lyophilized Injectables, Pre-Filled Syringes, Hormones, Ampoules and Biological Products.
Milestone/ Awards
2009
Venus Remedies - Product Patent for "TOBRACEF" granted in South Africa.
Venus Bags Another Product Patent from South Africa for POTENTOX.
2010
Venus Remedies receives GMP Certification from Botswana".
Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits.
The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015.
Venus Remedies research Blockbuster "Sulbactomax" gets European Union Patent"
2011
Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011.
Venus launches its patented research product ACHNIL” in India.
Venus Remedies wins ""India Manufacturing Excellence Award 2011.
2012
Venus Remedies introduces "Ready-to-Use"" Single Vial Taxedol in India
Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India
The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the "Industry 2.0 Manufacturing Innovation Conclave 2012.
Venus wins Patent award in Silver Category.
| 1 Day |
|
-1.83% |
| 1 Week |
|
+3.26% |
| 1 Month |
|
-21.47% |
| 3 Month |
|
-15.11% |
| 6 Month |
|
-41.11% |
| 1 Year |
|
-18.32% |
| 2 Year |
|
+430.49% |
| 5 Year |
|
+145.08% |
| 10 Year |
|
+57.01% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 17.04 | 15.38 | 1.12 | 0.38 | -4.13 | -8.18 | -8.23 | -3.05 | 17.40 | |
| Return on Capital Employed (%) | 14.85 | 14.06 | 5.74 | 5.35 | 2.00 | 1.17 | -0.67 | 0.90 | 12.37 | |
| Return on Assets (%) | 8.87 | 8.29 | 0.62 | 0.20 | -2.12 | -4.05 | -3.85 | -1.45 | 10.30 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
| Shh. Funds | 379 | 462 | 457 | 438 | 389 | 362 | 333 | 323 | 400 | 435 | |
| Non Curr. Liab. | 147 | 162 | 222 | 212 | 180 | 158 | 137 | 96 | 58 | 46 | |
| Curr. Liab. | 191 | 211 | 163 | 193 | 197 | 230 | 264 | 225 | 97 | 126 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 718 | 834 | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 607 | |
| Non Curr. Assets | 492 | 562 | 608 | 566 | 506 | 491 | 467 | 350 | 324 | 313 | |
| Curr. Assets | 226 | 272 | 233 | 277 | 259 | 260 | 265 | 294 | 232 | 294 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 718 | 834 | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 607 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
| Net Sales | 469 | 542 | 464 | 418 | 400 | 372 | 322 | 339 | 548 | 568 | |
| Other Income | 0 | 0 | 1 | 2 | 4 | 2 | 6 | 5 | 20 | 10 | |
| Total Income | 469 | 542 | 465 | 420 | 404 | 375 | 328 | 345 | 568 | 578 | |
| Total Expenditure | -349 | -403 | -375 | -337 | -349 | -333 | -289 | -299 | -494 | -507 | |
| PBIDT | 121 | 139 | 90 | 83 | 55 | 42 | 39 | 46 | 73 | 71 | |
| Interest | -25 | -29 | -41 | -38 | -36 | -36 | -25 | -13 | -13 | -1 | |
| Depreciation | -33 | -40 | -46 | -42 | -40 | -34 | -34 | -32 | -35 | -35 | |
| Taxation | -6 | -5 | 3 | -2 | 5 | -3 | 1 | -2 | 13 | 21 | |
| Exceptional Items | -9 | -9 | 23 | 21 | |||||||
| PAT | 57 | 64 | 5 | 2 | -17 | -31 | -29 | -10 | 62 | 76 | |
| Minority Interest | |||||||||||
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | 57 | 64 | 5 | 2 | -17 | -31 | -29 | -10 | 62 | 76 | |
| Adjusted EPS | 54 | 56 | 5 | 1 | -14 | -25 | -23 | -8 | 50 | 59 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 42 | 52 | 53 | 68 | 47 | 59 | 31 | 45 | 78 | 133 | |
| Cash Fr. Inv. | -95 | -104 | -95 | -67 | 3 | -18 | -11 | -11 | -5 | 56 | |
| Cash Fr. Finan. | 53 | 55 | 40 | -1 | -46 | -44 | -39 | -35 | -73 | -162 | |
| Net Change | 0 | 3 | -2 | -1 | 3 | -4 | -20 | -1 | 0 | 26 | |
| Cash & Cash Eqvt | 3 | 6 | 4 | 4 | 7 | 4 | -20 | 3 | 2 | 29 |
|
Mon, 16 May 2022
Board Meeting Intimation for Meeting Of Board Of Directors Is Scheduled To Be Held On 27Th May 2022. VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2022 inter alia to consider and approve This is to inform you that the meeting of Board of Directors is scheduled to be held on 27th May 2022 inter alia: 1. To consider and approve Audited Standalone and Consolidated Financial Results for the quarter and year ended on 31st March 2022. 2. Any other business with the permission of Chair. |
|
Thu, 12 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance Annual Secretarial Compliance Report of the Company for the year ended on 31st March 2022 as required under Regulation 24(A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 |
|
Tue, 19 Apr 2022
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation39(3) of the SEBI (LODR) notice is hereby given that the share certificate has been reported to be lost/ misplaced and the registered holders/claimant therefore have requested the Company for issuance of Duplicate Share Certificate(s) in lieu of lost share certificates(s. |
| Wed, 18 May 2022 |
Opening at High
|
Making Higher Highs for 3 days
|
High Decrease 1 Month
|
High Decrease 3 Months
|
High Decrease 6 Months
|
Equities
M.F.
Sectors